Brian G. Feagan - Concepedia

Author

Brian G. Feagan

Western University

Also Known As

Brian Feagan, Brian G Feagan, Brian G. Feagan

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Western University University of Calgary Mayo Clinic McMaster University University of Toronto

About

Brian G. Feagan is an author at Western University specializing in gastroenterology, medicine, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	399
2	Gastroenterology	4	4	504
3	Public Health	2	2	381
4	Epidemiology	2	2	381
5	Environmental Health	1	1	24

Brian G. Feagan

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort Marc D. Silverstein, Edward V. Loftus, William J. Sandborn, Gastroenterology Clinical CourseDisease ManagementHealth EconomicsPopulation-based CohortGastroenterology	1999	357
An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial William J. Sandborn, Brian G. Feagan, S. B. Hanauer, Gastroenterology InflammationMucosal ImmunologyMedicineImmunologyPathology	2001	252
Annual cost of care for Crohn's disease: a payor perspective Brian G. Feagan, Mary Glenn Vreeland, Leanne R. Larson, The American Journal of Gastroenterology	2000	192
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3 Jean–Frédéric Colombel, William J. Sandborn, Subrata Ghosh, The American Journal of Gastroenterology	2014	163
Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease Geert D’Haens, Florian Rieder, Brian G. Feagan, Gastroenterology InflammationFibrosisAutoimmune DiseaseMucosal ImmunologyIntestinal Fibrosis	2019	91
Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease Remo Panaccione, Richard N. Fedorak, Guy Anmais, Canadian Journal of Gastroenterology Chronic Inflammatory DiseasesOriginal GuidelinesCanadian AssociationGastroenterologyInflammatory Crohn	2004	32
Environmental Factors Associated With Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada - Genetic, Environmental, Microbial Project Mingyue Xue, Haim Leibovitzh, Shao Jingcheng, Clinical Gastroenterology and Hepatology DysbiosisMucosal ImmunologyEnvironmental HealthGastroenterologyEnvironmental Factors	2024	24
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials Remo Panaccione, Brian G. Feagan, Anita Afzali, The Lancet	2025	18
Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study Brian G. Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, Alimentary Pharmacology & Therapeutics	2024	10

Page 1